3. (Amended) A method according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.

4. (Amended) A method according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, a norethisterone ester, levonorgestrel, progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

5. (Amended) A method according to claim 1, wherein the antigestagen component is

4-[17β-Hydroxy-17α-(methoxymethyl)-3oxoestra-4,9-dien-11β-yl]benzaldehyde-1(E)-oxime (J 912);

4-[-17β-methoxy-17α-(methoxymethyl)-3-oxo-estra-4,9-dien-11β-yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime (J 1042);

4-[9α,10α-epoxy-17β-hydroxy-17α-(methoxymethyl)-3-oxo-estr-4-en-11β-yl]-benzaldehyde-1(E)-oxime (J 1116);

4-[17β-methoxy-17α-(methoxymethyl)-3oxoestra-4,9-dien-11β-yl]benzaldehyde-1(E)-oxime (J 867);

4-[17β-hydroxy-17α-(methoxymethyl)-3oxoestra-4,9-dien-11β-yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime (J 956);

11β-[(4-N,N-dimethylamino)-phenyl]-17β-hydroxy-17α-propinyl-estra-4,9-dien-3-one (RU 38 486 - mifepristone);

11β-][(4-N,N-dimethylamino)-phenyl]-17α-hydroxy-17β-(3-hydroxypropyl-13α-methyl-gona-4,9-dien-3-one (ZK 98299 - onapristone);

11β-(4-acetylphenyl)-17β-hydroxy-17α-propinyl-estra-4,9-dien-3-one (ZK 112993);

11β-[(4-N,N-dimethylamino)-phenyl]-17β-hydroxy-17α-(3-hydroxy-1-(Z)-propenyl)-estra-4,9-dien-3-one (ZK 98 734 - lilopristone);

11β-[(4-N,N-dimethylamino)-phenyl]-17β-hydroxy-17α-(3-hydroxy-1-(Z)-propenyl)-estra-4-en-3-one (ZK 137 316);

11β-[(4-N,N-dimethylamino)-phenyl]-6β-methyl-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 710);

11β-[(4-N,N-dimethylamino)-phenyl]-7β-methyl-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 806); or

11β-(4-acetylphenyl)-(3'E)-ethylidene-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3H)-furan]-3-one (ORG 33 628).

Please cancel claim 6 in its entirety.

7. (Amended) A method according to claim 1, wherein the GnRH-analog component is buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide or leuprolide acetate.

8. (Amended) A method according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.

9. (Amended) A method according to claim 1, wherein the testosterone-5α-reductase-inhibitor component is finasteride, epristeride, permixon, or turosteride.

10. (Amended) A method according to claim 1, wherein the α-andreno-receptor-blocker component is tolazoline, phentolamine, phenoxybenzamine, alfuzosin, or prazosin.

11. (Amended) A method according to claim 1, wherein the phosphodiesterase-inhibitor component is amrinone, milrinone, trapidil, papaverine, vesnarinone or sildenafil.

12. (Amended) A method of claim 1 wherein said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.